Laryngeal Cancer Symptoms, Stages and Treatment
In this article
What Are Laryngeal (Voice Box) and Hypopharyngeal (Lower Throat) Cancers?
Laryngeal (voice box) and hypopharyngeal (lower throat) cancers are important members of the head and neck cancer family, arising in two adjacent, functionally intertwined organs in the neck. The larynx is responsible for voice production, the reflex that protects the airway during swallowing, and breathing. The hypopharynx is a transition area between the pharynx (throat) and esophagus, surrounding the larynx. These organs are discussed together in this guide because they share risk factors (particularly smoking and alcohol), a similar histological type (squamous cell carcinoma, over 95%), and largely overlapping treatment principles; important differences, such as the markedly more insidious course and later-stage diagnosis of hypopharyngeal cancer, are also highlighted separately. In this guide, we discuss the causes, symptoms, diagnostic and staging methods, current treatment options, and the diagnostic and treatment process in Turkey for both cancers comprehensively and based on current literature.
The larynx and hypopharynx lie in the front-middle part of the neck, at the lower throat, adjacent to the beginnings of the windpipe (trachea) and esophagus. The great majority of laryngeal cancers (over 95%) and almost all hypopharyngeal cancers arise from the flat (squamous) epithelial cells lining these regions and are squamous cell carcinomas .
How Common Are They? (Current Statistics)
According to the report published by IARC on 8 July 2026 in CA: A Cancer Journal for Clinicians containing estimates for 2024, GLOBOCAN 2024 approximately 193.937 new laryngeal cancer cases occur worldwide each year (0,94% of all cancers, the 21st most common cancer), and approximately 96.619 people die from laryngeal cancer. There is an extremely marked sex difference: it is approximately 7 times more common in men than women (169.734 male cases versus 24.203 female cases). The same report lists hypopharyngeal cancer as a separate category: worldwide, approximately 91.464 new cases and 49.748 deaths occur each year, with a similarly male-dominated distribution (76.048 male cases, 15.416 female cases).
According to the Türkiye country fact sheet published by IARC in July 2026 as part of the same GLOBOCAN 2024 publication cycle, approximately 3.832 new laryngeal cancer cases are reported (1,6% of all cancers, the 15th most common cancer), and approximately 1.495 people die from laryngeal cancer. Turkey's age-standardized incidence rate (4,5 per 100.000), compared with the global average (1,9 per 100.000), is approximately 2,4 times as high — a marked difference directly reflecting the high prevalence of smoking in our country.
According to the American Cancer Society's "Cancer Statistics, 2026" report, published on 13 January 2026, the estimated number of new laryngeal cancer cases in the US for 2026 is 12.290 (9.730 men, 2.560 women), and the estimated number of deaths is 3.960. (Hypopharyngeal cancer is not reported separately in this annual US report but within the general "oral cavity and pharynx" category.) The 5-year relative survival rates, based on the SEER database and patients diagnosed between 2015-2021, reveal the striking difference between the two organs: for laryngeal cancer, overall survival is 57% (79% for localized disease, 49% for regional spread, 35% for distant metastases), while for hypopharyngeal cancer, overall survival is only %35 (61% for localized disease, 36% for regional spread, 20% for distant metastases).
The main reason for this marked survival difference, discussed in detail in the "Symptoms" section below, is that the anatomical location of the hypopharynx allows a growing tumor to remain unnoticed for a long time — hoarseness, an early warning sign in laryngeal cancer, is generally absent in hypopharyngeal cancer, leading to diagnosis mostly at an advanced stage (regional or distant metastatic disease).
Risk Factors
Smoking and alcohol use are the most important and dominant risk factors for laryngeal and hypopharyngeal cancers — when combined, their effects are not merely added, but increase in a multiplicative manner. The literature reports that laryngeal cancer risk in people who smoke and drink heavily, compared with those who do neither, is increased by 8-fold to over 100-fold ; some studies have reported increases up to 300-fold for oral and pharyngeal cancers. Having both habits therefore poses a danger far greater than the sum of their individual risks.
- Occupational exposures: Long-term exposure to asbestos, sulfur-containing gases, wood dust, and certain industrial chemicals may increase risk.
- Diet and reflux: A diet low in fruit and vegetables and chronic gastric acid reflux (particularly laryngopharyngeal reflux) are thought to contribute, but this association is much weaker and less certain than that of smoking/alcohol.
- Sex and age: As noted above, these cancers are markedly more common in men; risk increases with age, and diagnosis is usually made in the 60s.
Human papillomavirus (HPV) is a dominant cause of oropharyngeal (tonsil/base of tongue) cancers in the US, accounting for 60-70% of cases. However, the situation is different in laryngeal and hypopharyngeal cancers: The US Centers for Disease Control and Prevention (CDC) explicitly state that HPV is not known to cause other head and neck cancers, including laryngeal cancer. Although HPV DNA has been reported in approximately 28% of laryngeal tumor tissue samples, this does not mean that HPV has a proven causal/driver role as it does in the oropharynx — it merely demonstrates viral presence in the tissue. Therefore, unlike oropharyngeal cancer, HPV/p16 status does not routinely play a determining role in risk profiling and treatment decisions for laryngeal and hypopharyngeal cancers; smoking and alcohol remain the dominant factors.
Anatomy: Subregions of the Larynx and Hypopharynx
The subregion in which a tumor originates within the larynx or hypopharynx directly affects symptoms, its tendency to spread, and treatment selection.
- Supraglottis (upper region): Includes the epiglottis, aryepiglottic folds, and false vocal cords. Tumors here may cause no early symptoms and are generally noticed as a palpable neck mass (lymph node metastasis), because this region has rich lymphatic drainage.
- Glottis (middle region, true vocal cords): This is the most common tumor location. Because even the smallest tumor here causes hoarseness, glottic tumors are generally diagnosed at an early stage — the main reason laryngeal cancer generally has a better prognosis. Lymphatic drainage of the true vocal cords is also relatively sparse, explaining why lymph node metastases are rare at an early stage.
- Subglottis (lower region): This extends beneath the vocal cords to the trachea; its tumors are the rarest and are generally detected at a late stage through breathing difficulty.
- Pyriform sinus (pear-shaped recess): Most hypopharyngeal tumors (60-85%) originate here.
- Postcricoid region: Less common; reported relatively more often in women with Plummer-Vinson (Paterson-Kelly) syndrome associated with chronic iron deficiency anemia.
- Posterior pharyngeal wall: This is the rarest subregion.
What Are the Symptoms?
Particularly in glottic (vocal cord) tumors, unexplained hoarseness lasting longer than 2-3 weeks is generally the first and earliest symptom — the main reason laryngeal cancer can be detected relatively early.
- Hoarseness lasting longer than 2-3 weeks
- Difficulty swallowing (dysphagia)
- Pain on swallowing (odynophagia)
- A persistent feeling of something stuck/a foreign body in the throat
- Referred ear pain (particularly on the same side)
- A palpable swelling or mass in the neck
- Shortness of breath or difficulty breathing (which may be due to airway obstruction at an advanced stage)
- Chronic cough
- Unexplained weight loss
- Blood-stained saliva or sputum from the mouth
The anatomical location of the hypopharynx allows a tumor to grow unnoticed for a long time without an obvious early warning sign comparable to hoarseness in laryngeal cancer. A substantial proportion of patients with hypopharyngeal cancer therefore present initially with a palpable neck mass (meaning disease has already spread to a lymph node); swallowing difficulty and weight loss also often appear only when disease is well advanced. This is the fundamental mechanism explaining why hypopharyngeal cancer is generally diagnosed later and has a worse prognosis than laryngeal cancer.
Many of these symptoms can also arise from benign causes, such as upper respiratory infections. However, people with a history of smoking and/or alcohol use should promptly consult an ear, nose, and throat specialist, particularly for hoarseness lasting longer than 3 weeks, an unexplained neck mass, or swallowing difficulty.
How Is the Diagnosis Made?
- Laryngoscopy: Direct visualization of the larynx and hypopharynx with a fiberoptic or rigid endoscope is the first and fundamental diagnostic step.
- Biopsy: Definitive diagnosis is made by pathological examination of tissue sampled from a suspicious lesion.
- Imaging: Neck computed tomography (CT) or magnetic resonance imaging (MRI) is used to assess tumor spread into deeper structures (cartilage, anterior neck tissues) and lymph node involvement. PET-CT is valuable for investigating distant metastases and a synchronous (simultaneous) second tumor.
- Panendoscopy: This procedure, assessing the larynx, hypopharynx, esophagus, and sometimes bronchi together under general anesthesia, is often performed to screen for a synchronous second tumor because of "field cancerization," discussed separately below.
Because smoking and alcohol similarly affect the lining of the entire upper aerodigestive tract (mouth, pharynx, larynx, esophagus, lungs), patients diagnosed with cancer in this region have a markedly higher risk than the general population of developing a second cancer elsewhere, either simultaneously or later — a phenomenon called "field cancerization." Assessing the esophagus and lungs at diagnosis and regularly monitoring them during long-term follow-up after treatment are therefore important.
Staging: the TNM System (AJCC 8th Edition)
Laryngeal and hypopharyngeal cancers are staged using the internationally accepted TNM system ; the T category is defined separately for each organ using criteria specific to its subregions, while the N (regional lymph node) and M (distant metastasis) categories are largely shared with other head and neck cancers.
| T (Larynx — General Approach) | Definition |
|---|---|
| T1 | Tumor confined to a single subregion (for example, one vocal cord), normal mobility |
| T2 | Tumor extends into an adjacent subregion or vocal cord mobility is impaired |
| T3 | Vocal cord fixed (immobile), or involvement of the inner cartilage surface, or limited spread beyond the larynx |
| T4 | Spread through the thyroid cartilage or into adjacent structures outside the larynx (neck soft tissue, thyroid gland, esophagus, trachea) |
| T (Hypopharynx — General Approach) | Definition |
|---|---|
| T1 | Tumor ≤2 cm and confined to a single subregion |
| T2 | Tumor 2-4 cm or extending into more than one subregion/an adjacent region, without fixation of the hemilarynx |
| T3 | Tumor >4 cm, or fixation of the hemilarynx (immobility of the vocal cord/half of the larynx), or extension into the esophagus |
| T4 | Invasion of thyroid/cricoid cartilage, hyoid bone, thyroid gland, or neck soft tissue (T4a); or invasion of prevertebral fascia, carotid artery, or mediastinal structures (T4b) |
The T categories above are combined with N (lymph node) and M (metastasis) status to group disease from Stage I to Stage IVC. In general, Stage I-II describes early disease (confined to one organ, without lymph node involvement), Stage III-IVA locally advanced disease (lymph node involvement or limited spread into adjacent structures), Stage IVB very advanced local/regional disease, and Stage IVC distant metastatic disease. Lymph node involvement at diagnosis is markedly more common in hypopharyngeal than laryngeal cancer — consistent with the pattern of late symptomatic presentation described above.
Treatment of Laryngeal Cancer: an Organ-Preserving Approach
Early-Stage (T1-T2) Laryngeal Cancer
In early-stage tumors, particularly glottic tumors, the aim is to cure disease while preserving voice and swallowing as much as possible. Two main options provide similar cure rates: radiotherapy alone or transoral laser microsurgery (TLM)/in selected cases, transoral robotic surgery (TORS). Although no randomized controlled trial directly compares these approaches, numerous observational/comparative studies show similar oncological outcomes with both; choice depends on the tumor's precise location, the patient's preferences, and the center's experience.
Organ Preservation in Locally Advanced Laryngeal Cancer
Conducted in the early 1990s, the VA Laryngeal Trial showed that induction chemotherapy followed by radiotherapy could preserve the larynx (and thus voice) in a substantial proportion of patients with locally advanced laryngeal cancer while providing survival comparable to immediate total laryngectomy. This finding was developed further in RTOG 91-11 , which compared induction chemotherapy plus radiotherapy, concurrent chemoradiotherapy , and radiotherapy alone. At a median follow-up of 10,8 years (2013 update), concurrent chemoradiotherapy showed superiority in larynx preservation over both the induction arm (HR 0,58) and radiotherapy-alone arm (p<0,001), becoming today's standard.
Long-term follow-up of RTOG 91-11 found no statistically significant overall survival difference among the three arms. Notably, the concurrent chemoradiotherapy arm showed a negative overall survival trend approaching significance compared with the induction arm (HR 1,25; p=0,08) — thought to be partly related to late toxicity and noncancer deaths. This nuance is important information to share with patients: "the highest larynx preservation rate" and "the best overall outcome" may not always coincide.
Total Laryngectomy
In bulky tumors (marked cartilage invasion, major loss of laryngeal function, or disease that fails to respond to organ-preserving treatment/recurs), complete surgical removal of the larynx (total laryngectomy) may be necessary. The patient then breathes through a permanent neck tracheostomy (an opening into the windpipe), and voice/swallowing rehabilitation (discussed below) becomes very important.
The Specific Treatment Approach in Hypopharyngeal Cancer
As in laryngeal cancer, the scientific basis for organ preservation in hypopharyngeal cancer was established by EORTC 24891 : this trial compared induction chemotherapy followed by radiotherapy with immediate surgery followed by radiotherapy and showed that, without an overall survival difference, the larynx (and swallowing) could be preserved in a substantial proportion of patients responding to induction chemotherapy. The 10-year follow-up confirmed this finding.
However, organ preservation is generally less successful in hypopharyngeal than laryngeal cancer; because disease is more often diagnosed with lymph node involvement at a more advanced stage, many patients (particularly with T3-T4 disease) may require surgery (partial or total pharyngectomy/laryngectomy, with removal of part of the esophagus when needed) together with reconstructive surgery (reconstruction of the pharynx/esophagus with a free tissue flap).
Treatment of Neck Lymph Nodes
In cancers of either organ, neck lymph node regions with involvement on imaging or clinical examination, or considered at high risk of involvement, are treated with neck dissection (surgery) or included in the radiotherapy field. In hypopharyngeal cancer, treatment of both sides of the neck is often necessary because lymphatic spread is common and generally bilateral.
Voice and Swallowing Rehabilitation
Loss of voice after total laryngectomy profoundly affects quality of life; several effective rehabilitation options are now available:
- Tracheoesophageal puncture (TEP) and a voice prosthesis: A small one-way valve/prosthesis placed between the windpipe and esophagus allows air from the lungs to vibrate the esophagus and produce sound; this is currently the most commonly preferred method and produces the closest result to a natural voice.
- Electrolarynx (electronic larynx): An electronic device placed against the neck skin to produce sound through vibration.
- Esophageal speech: A technique requiring training, based on learning to produce sound by releasing swallowed air in a controlled manner.
Support from a speech and swallowing therapist (speech-language therapist) is an integral part of postoperative rehabilitation.
Systemic Treatment of Metastatic or Recurrent Disease
For distant metastases or recurrence unsuitable for local/regional treatment, the systemic approach largely overlaps with that for other head and neck squamous cell cancers (oral cavity, oropharynx).
In recurrent/metastatic nonnasopharyngeal head and neck squamous cell cancer, KEYNOTE-048 largely superseded the previous standard EXTREME regimen (cetuximab+platinum+5-FU): in patients with PD-L1 CPS ≥1, pembrolizumab alone, and in all patients, pembrolizumab+chemotherapy became the current first-line standard. The subsequent period is called the "post-KEYNOTE-048 era" in the literature, and as of 2026 no new first-line trial has replaced this approach.
In patients with progression after platinum-based treatment, based on CheckMate 141, nivolumab demonstrated superior overall survival compared with standard investigator-selected treatment (chemotherapy), becoming a standard second-line option for this group; as of 2026 there has been no new approval in this area.
For patients unable to tolerate cisplatin-based chemoradiotherapy ("cisplatin-ineligible" because of renal failure, hearing loss risk, frailty, or similar reasons), cetuximab+radiotherapy (the Bonner regimen) remains an alternative treatment for locally advanced disease. Published in 2024, NRG-HN004 showed that durvalumab+radiotherapy was not superior to cetuximab+radiotherapy in this group, reinforcing cetuximab's place in these specific cisplatin-ineligible patients.
On 12 June 2025, the FDA approved a new approach for surgically treatable, locally advanced (Stage III/IVA) head and neck squamous cell cancer with PD-L1 CPS ≥1 (including laryngeal/hypopharyngeal cancer): treatment before surgery with 2 cycles of neoadjuvant pembrolizumab, followed by surgery, then adjuvant pembrolizumab with radiotherapy (± cisplatin), and finally continued pembrolizumab alone. This regimen is based on KEYNOTE-689. In the CPS≥10 subgroup, median event-free survival was reported as 59,7 months versus 26,9 months compared with standard treatment (HR 0,66). This is one of the field's most recent and important advances, bringing immunotherapy to the very beginning of treatment (before surgery) in surgically treatable head and neck cancer.
Presented at ASCO 2025, NIVOPOSTOP (GORTEC 2018-01) showed that adjuvant nivolumab added to standard chemoradiotherapy in operated head and neck cancer patients at high recurrence risk markedly improved 3-year recurrence-free survival (63,1% versus 52,5%) — investigators describe it as "the first trial to improve the postoperative standard of care in the past 20 years." However, overall survival data are not yet mature, and as of August 2026 this approach has not received FDA approval; we recommend that our readers continue to follow this development.
Treatment Side Effects and Their Management
Radiotherapy-Related Side Effects
The most common side effects of head and neck radiotherapy include mucositis (painful inflammation of the mouth/throat lining), dry mouth (xerostomia) — often a potentially permanent effect of damage to the salivary glands, changes in/loss of taste, swallowing difficulty , and long-term fibrosis (hardening) of the neck tissues. For dental health, dental assessment before treatment and long-term fluoride-based dental care afterward are important (to reduce the risk of radiation-related jawbone damage — osteoradionecrosis).
Chemotherapy and Targeted/Immunotherapy Drugs
Cisplatin can cause renal toxicity, hearing loss (ototoxicity), and nausea; use is therefore limited in patients with impaired renal function or high hearing loss risk (as described above, cetuximab+RT may be an alternative for these patients). Cetuximab characteristically carries a risk of acneiform rash and infusion reactions. Pembrolizumab and nivolumab are immunotherapy drugs that can cause irAEs (colitis, hepatitis, pneumonitis, endocrine disorders, skin reactions) through excessive immune activation; management is based on severity grading.
Diagnosis, Licensing, and Reimbursement in Turkey
Laryngeal and hypopharyngeal cancer diagnosis and treatment in Turkey are carried out in ear, nose, and throat, radiation oncology, and medical oncology centers at university and training/research hospitals, in line with international guidelines. For drugs to be used in Turkey, TİTCK licensing is required first; for SGK coverage, a separate reimbursement decision under SUT is also necessary.
Standard chemotherapy drugs (cisplatin, carboplatin, 5-FU, docetaxel, paclitaxel) have long been licensed and covered by SGK. Cetuximab has long been licensed and covered by SGK both with radiotherapy for locally advanced disease (Bonner regimen) and with first-line platinum-based chemotherapy for recurrent/metastatic disease. The SUT update of 10 July 2025 brought pembrolizumab (CPS>1, first line in recurrent/metastatic nonnasopharyngeal disease, alone or with platinum+5-FU) and nivolumab (a second-line single agent in patients recurring within the first 6 months after first-line platinum-based treatment) under SGK reimbursement — an important advance compared with previous years, when these two drugs were not covered by SGK for head and neck cancer.
According to our sources, although second-line single-agent pembrolizumab (PD-L1 TPS≥50%, progression after platinum) is licensed in Turkey, SGK coverage for this specific indication could not be clearly verified. The licensing and reimbursement status in Turkey of perioperative pembrolizumab (KEYNOTE-689), FDA-approved in 2025, may also remain unclear because approval is recent.
Drug authorization and reimbursement status can change frequently with SUT updates. The information in this section is a general summary compiled as of the article's update date (August 2026); always confirm definitive and current information about your individual treatment and reimbursement situation with your treating physician and SGK's current SUT text.
Frequently Asked Questions
- I have hoarseness; does this necessarily mean cancer?
- No; much more common causes of hoarseness exist (laryngitis, vocal cord nodules, reflux). However, unexplained hoarseness lasting longer than 2-3 weeks, particularly in people with a smoking/alcohol history, must be assessed by an ear, nose, and throat specialist.
- Will I be unable to speak after total laryngectomy?
- No. Through tracheoesophageal puncture and a voice prosthesis, an electrolarynx, or esophageal speech techniques, the great majority of patients whose larynx is completely removed can regain the ability to speak; support from a speech therapist is important during this process.
- Why is hypopharyngeal cancer generally diagnosed late?
- Unlike laryngeal cancer, hypopharyngeal cancer generally has no obvious early warning sign, such as hoarseness; a tumor may go unnoticed until it grows enough to cause a palpable neck mass or swallowing difficulty becomes marked. An unexplained neck mass in people with a smoking/alcohol history must therefore be assessed.
- Am I at risk of developing another cancer after treatment?
- Because smoking and alcohol similarly affect the entire upper aerodigestive tract ("field cancerization"), people who have had cancer in this region have an increased risk of a second cancer in the esophagus and lungs. Regular follow-up and completely stopping smoking/alcohol after treatment are therefore very important.
- Sung H, et al. "Global cancer statistics 2024." CA: A Cancer Journal for Clinicians, 2026. DOI: 10.3322/caac.70090
- IARC Global Cancer Observatory (GLOBOCAN 2024) — Larynx and Hypopharynx Cancer Fact Sheets, Turkey Country Fact Sheet. gco.iarc.who.int
- Siegel RL, et al. "Cancer Statistics, 2026." CA: A Cancer Journal for Clinicians, 2026. DOI: 10.3322/caac.70043
- SEER Cancer Stat Facts: Larynx and Hypopharyngeal Cancer, 2015-2021 cohort data. seer.cancer.gov
- Testa U, et al. "Cancer Risk Associated with Alcohol and Tobacco Use." 2019 review.
- CDC. "HPV and Oropharyngeal Cancer" — statement on HPV's limited role in laryngeal/hypopharyngeal cancer. cdc.gov
- The Department of Veterans Affairs Laryngeal Cancer Study Group. "Induction Chemotherapy plus Radiation Compared with Surgery plus Radiation in Patients with Advanced Laryngeal Cancer." NEJM, 1991.
- Forastiere AA, et al. "Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx." J Clin Oncol, 2013.
- Lefebvre JL, et al. EORTC 24891 — hypopharyngeal/laryngeal preservation trial, 10-year follow-up. Ann Oncol, 2012.
- Burtness B, et al. "Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy" (KEYNOTE-048). Lancet, 2019.
- Ferris RL, et al. "Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck" (CheckMate 141). NEJM, 2016.
- Bonner JA, et al. "Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck." NEJM, 2006.
- NRG Oncology. NRG-HN004 — durvalumab+RT vs cetuximab+RT, cisplatin-ineligible patients. Lancet Oncology, 2024.
- FDA approval announcement: Perioperative pembrolizumab, resectable locally advanced HNSCC (KEYNOTE-689), 12 June 2025. fda.gov; Wan H, et al. NEJM, 2024-2025.
- GORTEC 2018-01 (NIVOPOSTOP) — ASCO 2025 presentation, adjuvant nivolumab data.
- Communiqué Amending the Healthcare Implementation Communiqué, 10 July 2025 (SGK SUT update).
Was this article helpful?
Your feedback helps us improve our content.
